OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx
September 27 2016 - 8:30AM
Business Wire
OPKO Health, Inc. (NASDAQ:OPK), announces the appointment
of Benjamin D. Solomon, M.D. as Managing Director of GeneDx,
effective as of October 3, 2016. GeneDx, part of OPKO’s
BioReference Laboratories subsidiary, specializes in genetic
testing for rare hereditary disorders.
Dr. Solomon is a pediatric geneticist who focuses on the use of
genetics and genomics to identify, understand and care for patients
with both rare and common genetic conditions. He is a leader in
integrating cutting-edge technologies to better manage health and
disease. He most recently served as Chief of the Division of
Medical Genomics at the Inova Translational Medicine Institute, a
clinical research institute dedicated to putting genomic medicine
into action.
“We are very proud to have Dr. Solomon join the OPKO Health team
as the new leader of our GeneDx division, a world-class genomics
laboratory. A recognized leader in his field, Dr. Solomon’s
expertise in genomics and genetics will be of great value as we
continue to leverage leading technologies to build and expand
GeneDx’s global role in diagnostic and laboratory services. His
passion for finding answers for patients and clinicians and his
talent and experience in the integration of genomics into the
practice of medicine will enhance the numerous and diverse
communities in the U.S. and worldwide that benefit from the
outstanding diagnostic services our laboratories offer,” said
Gregory S. Henderson, M.D., Ph.D., President of BioReference
Laboratories.
In addition to his clinical and research leadership and
advocacy, Dr. Solomon has published more than 100 peer-reviewed
articles and book chapters, is co-editor of the most recent edition
of the textbook Human Malformations, and is an active lecturer and
educator. Dr. Solomon attended medical school at the Geisel School
of Medicine at Dartmouth College and completed his residency and
fellowship training in pediatric medicine and clinical genetics at
the National Human Genome Research Institute at the National
Institutes of Health and at Children’s National Medical Center. He
is board-certified in clinical genetics and pediatrics.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks
to establish industry-leading positions in large, rapidly growing
markets. Our diagnostics business includes BioReference
Laboratories, the nation's third-largest clinical laboratory with a
core genetic testing business and a 420-person sales force to drive
growth and leverage new products, including the 4Kscore® prostate
cancer test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE®, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency, and VARUBI™ for chemotherapy-induced nausea and
vomiting (oral formulation launched by partner Tesaro and IV
formulation PDUFA is January 2017). Our biologics business includes
hGH-CTP, a once-weekly human growth hormone injection (in Phase 3
and partnered with Pfizer), a long-acting Factor VIIa drug for
hemophilia (in Phase 2a) and a long-acting oxyntomodulin for
diabetes and obesity (in Phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information is
available at www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
synergies, benefits and opportunities of the transaction, future
opportunities for the combined company and products, the potential
for Transition Therapeutics’ products and whether they will benefit
patients suffering with metabolic and androgen deficiency diseases,
the growth, development and strength of OPKO’s pipeline, as well as
other non-historical statements about our expectations, beliefs or
intentions regarding our business, technologies and products,
financial condition, strategies or prospects. Many factors could
cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking
statements. These factors include those described in our Annual
Reports on Form 10-K filed and to be filed with the Securities and
Exchange Commission and in our other filings with the Securities
and Exchange Commission. The forward-looking statements contained
in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the
PSLRA.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160927005597/en/
OPKO Health, Inc.CompanyTara Mackay, 305-575-4100Investor
RelationsorMediaRooneyPartnersTerry Rooney,
212-223-0689trooney@rooneyco.comorMarion Janic,
212-223-4017mjanic@rooneyco.comorInvestorsLHAAnne Marie
Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024